Valuation: CSL Limited

Market Cap 60.65B 52.56B 49.68B 45.1B 84.53B 5,819B 85.04B 593B 229B 2,951B 228B 223B 9,407B P/E 2027 *
20.7x
P/E 2028 * 18.8x
Enterprise Value 69.83B 60.52B 57.2B 51.93B 97.32B 6,699B 97.9B 683B 264B 3,398B 262B 256B 10,830B EV / Sales 2027 *
4.43x
EV / Sales 2028 * 4.26x
Free-Float
99.97%
Yield 2027 *
2.37%
Yield 2028 * 2.51%
1 day+1.57%
1 week+2.38%
Current month+1.57%
1 month+29.00%
3 months+76.71%
6 months+27.72%
Current year+8.40%
1 week 24
Extreme 24
26.4
1 month 22.8
Extreme 22.8
26.4
Current year 12.7
Extreme 12.7
43.4
1 year 12.7
Extreme 12.7
43.4
3 years 12.7
Extreme 12.7
47.5
5 years 12.7
Extreme 12.7
51
10 years 12.7
Extreme 12.7
52.5
Manager TitleAgeSince
Chief Executive Officer 63 11/02/2026
Director of Finance/CFO 52 07/10/2025
Chief Operating Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 72 17/10/2018
Director/Board Member 70 02/02/2011
Director/Board Member 71 09/12/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+2.38% - - 59.58B
+0.80%-1.45%+33.52%-5.19% 77.35B
+1.81%+3.71%-12.06%-33.66% 59.58B
+9.10%+15.96%+533.70%+52.13% 58.14B
-0.92%-3.86%-12.36%+24.21% 47.62B
+1.21%+3.42%+2.76%+151.63% 45.34B
+0.82%+0.78%+49.87%-14.29% 31.92B
+1.33%+2.65%+49.23%+112.65% 25.29B
+2.18%-2.09%-0.10%+145.28% 20.88B
+1.46%+1.60%+62.58%+102.27% 15.64B
Average +1.89%+0.11%+78.57%+59.45% 42.42B
Weighted average by Cap. +2.04%+0.39%+94.96%+41.07%

Financials

2027 *2028 *
Net sales 15.76B 13.66B 12.91B 11.72B 21.97B 1,512B 22.1B 154B 59.56B 767B 59.22B 57.9B 2,445B 16.31B 14.14B 13.36B 12.13B 22.74B 1,565B 22.87B 160B 61.64B 794B 61.29B 59.93B 2,530B
Net income 2.84B 2.46B 2.33B 2.11B 3.96B 272B 3.98B 27.76B 10.73B 138B 10.67B 10.43B 440B 3.17B 2.75B 2.6B 2.36B 4.42B 304B 4.44B 30.99B 11.97B 154B 11.91B 11.64B 492B
Net Debt 9.18B 7.95B 7.52B 6.82B 12.79B 880B 12.87B 89.74B 34.68B 447B 34.48B 33.71B 1,423B 8.87B 7.69B 7.27B 6.6B 12.36B 851B 12.44B 86.74B 33.52B 432B 33.32B 32.58B 1,376B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change
17/09/26 25.80 +1.57%
16/09/26 €25.40 -3.79%
15/09/26 €26.40 +2.33%
14/09/26 €25.80 +7.50%
11/09/26 €24.00 -4.76%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
126.65USD
Average target price
123.59USD
Spread / Average Target
-2.41%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!